

# MOLECULAR PHARMACOLOGY

September 2016

Volume 90

Number 3

molpharm.aspetjournals.org

ISSN 1521-0111

## SPECIAL SECTION—A LATIN AMERICAN PERSPECTIVE ON ION CHANNELS

### A Latin American Perspective on Ion Channels

*Ana Belén Elgoyhen and Carlos Barajas-López*

286

### Understanding the Bases of Function and Modulation of $\alpha 7$ Nicotinic Receptors: Implications for Drug Discovery

*Jeremías Corradi and Cecilia Bouzat*

288

### Structure-Driven Pharmacology of Transient Receptor Potential Channel Vanilloid 1

*Ignacio Díaz-Franulic, Javier Caceres-Molina, Romina V. Sepulveda, Fernando Gonzalez-Nilo, and Ramon Latorre*

300

### Gating, Regulation, and Structure in $K_{2P}$ $K^+$ Channels: *In Varietate Concordia?*

*María Isabel Niemeyer, L. Pablo Cid, Wendy González, and Francisco V. Sepúlveda*

309

### Structure and Pharmacologic Modulation of Inhibitory Glycine Receptors

*Carlos F. Burgos, Gonzalo E. Yévenes, and Luis G. Aguayo*

318

### Dynamic Regulation of the GABA<sub>A</sub> Receptor Function by Redox Mechanisms

*Daniel J. Calvo and Andrea N. Beltrán González*

326

### Pharmacological Conversion of a Cardiac Inward Rectifier into an Outward Rectifier Potassium Channel

*Eloy G. Moreno-Galindo, Jose A. Sanchez-Chapula, Martin Tristani-Firouzi, and Ricardo A. Navarro-Polanco*

334

### Modulation of Ionic Channels and Insulin Secretion by Drugs and Hormones in Pancreatic Beta Cells

*Myrian Velasco, Carlos Manlio Díaz-García, Carlos Larqué, and Marcia Hiriart*

341

### Channels and Volume Changes in the Life and Death of the Cell

*Herminia Pasantes-Morales*

358

### Modulation of Autophagy by Calcium Signalosome in Human Disease

*Eduardo Cremonese Filippi-Chiela, Michelle S. Viegas, Marcos Paulo Thomé, Andreia Buffon, Marcia R. Wink, and Guido Lenz*

371

### Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives.

*Audry Fernández, Amaury Pupo, Karel Mena-Ulecia, and Carlos Gonzalez*

385

### Calcium Channels and Associated Receptors in Malignant Brain Tumor Therapy

*Fernanda B. Morrone, Marina P. Gehring, and Natália F. Nicoletti*

403

## MINIREVIEW

### Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer

*Erik S. Blomain, Dante J. Merlino, Amanda M. Pattison, Adam E. Snook, and Scott A. Waldman*

199

## ARTICLES


- Quantitative Single-Cell Analysis of Signaling Pathways Activated Immediately Downstream of Histamine Receptor Subtypes  
*Jakobus van Unen, Ali Rashidfarrokhi, Eelco Hoogendoorn, Marten Postma, Theodorus W. J. Gadella Jr., and Joachim Goedhart* 162
- Characterization of a Novel M<sub>1</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [<sup>3</sup>H]PT-1284  
*Deborah L. Smith, Jennifer E. Davoren, Jeremy R. Edgerton, John T. Lazzaro, Che-Wah Lee, Sarah Neal, Lei Zhang, and Sarah Grimwood* 177
- Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers  
*Chunlong Ma, Jiantao Zhang, and Jun Wang* 188
- Involvement of Spinal Angiotensin II System in Streptozotocin-Induced Diabetic Neuropathic Pain in Mice  
*Yoshiki Ogata, Wataru Nemoto, Osamu Nakagawasai, Ryota Yamagata, Takeshi Tadano, and Koichi Tan-No* 205
- Dihydromunduletone Is a Small-Molecule Selective Adhesion G Protein–Coupled Receptor Antagonist  
*Hannah M. Stoveken, Laura L. Bahr, M. W. Anders, Andrew P. Wojtovich, Alan V. Smrcka, and Gregory G. Tall* 214
- Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells  
*Rayna Rosati, Bailing Chen, Mugdha Patki, Thomas McFall, Siyu Ou, Elisabeth Heath, Manohar Ratnam, and Zhihui Qin* 225
- Aberrant Subcellular Dynamics of Sigma-1 Receptor Mutants Underlying Neuromuscular Diseases  
*Adrian Y. C. Wong, Elitza Hristova, Nina Ahlskog, Louis-Alexandre Tasse, Johnny K. Ngsee, Prakash Chudalayandi, and Richard Bergeron* 238
- Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1  
*Lucy J. Martínez-Guerrero, Mark Morales, Sean Ekins, and Stephen H. Wright* 254
- Induction of the UDP-Glucuronosyltransferase 1A1 during the Perinatal Period Can Cause Neurodevelopmental Toxicity  
*Rika Hirashima, Hirofumi Michimae, Hiroaki Takemoto, Aya Sasaki, Yoshinori Kobayashi, Tomoo Itoh, Robert H. Tukey, and Ryoichi Fujiwara* 265
- Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate  
*Wen-Ying Lin, Yoshiro Sohma, and Tzyh-Chang Hwang* 275

## NOTICE OF RETRACTION

- Re: Abkhezr M and Dryer SE (2014) Angiotensin II and Canonical Transient Receptor Potential-6 Activation Stimulate Release of a Signal Transducer and Activator of Transcription 3–Activating Factor from Mouse Podocytes *Mol Pharmacol* August 2014 86:150–158; doi:10.1124/mol.114.092536 160
- Re: Abkhezr M and Dryer SE (2015) STAT3 Regulates Steady-State Expression of Synaptopodin in Cultured Mouse Podocytes *Mol Pharmacol* February 2015 87:231–239; doi:10.1124/mol.114.094508 161

## ERRATUM

Correction to “ $\alpha 7\beta 2$ Nicotinic Acetylcholine Receptors Assemble, Function, and Are Activated Primarily via Their $\alpha 7$ - $\alpha 7$ Interfaces”	410
Correction to: Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified Through Structure-based Design	411
Correction to “Quantitative Single-Cell Analysis of Signaling Pathways Activated Immediately Downstream of Histamine Receptor Subtypes”	413

 Supplemental material is available online at <http://molpharm.aspetjournals.org>.

*About the cover:* Atomistic representation of PI(4,5)P2 binding site in TRPV1 channel. See the article by Latorre et al. ([dx.doi.org/10.1124/mol.116.104430](https://doi.org/10.1124/mol.116.104430)).